Previous Close | 11.76 |
Open | 11.80 |
Bid | 10.76 x 800 |
Ask | 12.04 x 800 |
Day's Range | 11.44 - 12.15 |
52 Week Range | 4.82 - 14.92 |
Volume | |
Avg. Volume | 257,426 |
Market Cap | 566.801M |
Beta (5Y Monthly) | 1.27 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.38 |
Earnings Date | Nov 13, 2023 - Nov 17, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 18.20 |
Subscribe to Yahoo Finance Plus to view Fair Value for ALPN
Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.
SEATTLE, September 12, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced that the Company presented new preclinical data from a study of povetacicept in a murine experimental autoimmune myasthenia gravis (EAMG) model during the 148th Annual American Neurological Association (ANA) Meeting in Philadelphia, PA. In addition, the Company presented safety, tol
Here is how Si-Bone (SIBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.